Evidence map›Paper›PMID 42837018›Full record

ReviewActa neuropathologica2026

SOD1 co-pathologies in the brain: insights from neuropathological evidence and implications.

Evellyn Mayla de Azevedo, Victoria Simões Bernardo, Marcelo M S Lima, Elis Cristina Araujo Eleutherio, Tiago Fleming Outeiro

Abstract readReview
In one paragraph

Review in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Evellyn Mayla de Azevedo *Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.ORCID http://orcid.org/0000-0002-1549-1098
Victoria Simões Bernardo *Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.ORCID http://orcid.org/0000-0003-3353-9056
Marcelo M S LimaNeurophysiology Laboratory, Department of Physiology, Biological Sciences Center, Universidade Federal Do Paraná (UFPR), Curitiba, PR, Brazil.ORCID http://orcid.org/0000-0001-9602-4880
Elis Cristina Araujo EleutherioInstitute of Chemistry, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. eliscael@iq.ufrj.br.ORCID http://orcid.org/0000-0001-5842-2714
Tiago Fleming OuteiroDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany. touteiro@gmail.com.ORCID http://orcid.org/0000-0003-1679-1727

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 300367/2026-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 309635/2023-3Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88881.986154/2024-01Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.169657/2025-00Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro 210.034/2026
6 · The paper itself

Abstract

Superoxide dismutase 1 (SOD1), originally regarded as an antioxidant enzyme, is now recognized as a multifunctional protein whose conformational instability and aggregation contribute to neurodegeneration. The emerging evidence suggests that SOD1 pathology extends beyond amyotrophic lateral sclerosis, supporting a role in multiple neurodegenerative diseases. This review summarizes current neuropathological evidence of SOD1 co-pathologies in the human brain, with particular emphasis on its associations with TAR DNA-binding protein 43 (TDP-43), tau, alpha-synuclein, amyloid-β, and other aggregation-prone proteins. We examine the distribution of pathological SOD1 species across neurodegenerative diseases, their coexistence in affected brain regions, and potential mechanisms underlying these interactions, including oxidative stress, impaired proteostasis, aberrant phase separation, and cross-seeding. We also discuss emerging observations of SOD1 pathology in neurological conditions beyond classical neurodegenerative diseases, raising the possibility that SOD1 misfolding represents a broader cellular response to neuronal injury. Collectively, the available evidence supports a shift from viewing SOD1 as a disease-specific protein to considering it a potential participant in interconnected proteopathic networks. Although the functional significance of SOD1 co-pathologies remains incompletely understood, elucidating the molecular basis of aggregation may provide new insights into disease onset and progression, improving our understanding of neurodegenerative mechanisms, and facilitating the development of biomarkers and the identification of therapeutic targets across diverse proteinopathies.

Indexed as

BrainNeurodegenerative DiseasesSuperoxide Dismutase-1Amyotrophic Lateral SclerosisAnimalsHumansSOD1 protein, humanSuperoxide Dismutase-1ALSCo-pathologiesFTDNeuropathologyProtein aggregation

Identifiers

PMID42837018
PMCPMC13642433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.